Core Viewpoint - The successful export of the quadrivalent influenza virus subunit vaccine, Hui Er Kang Xin, to the Macau Special Administrative Region marks a significant milestone in the company's internationalization strategy and showcases its research and production capabilities on a global scale [1][2][3] Group 1: Vaccine Details - The quadrivalent influenza virus subunit vaccine utilizes advanced third-generation technology, containing major surface antigens from two types of influenza A and two types of influenza B, ensuring high purity, safety, and strong immunogenicity [1] - Compared to traditional vaccines, this product has optimized processes that significantly enhance vaccination safety and protective effects, making it suitable for various groups, including high-risk populations [1] Group 2: Market Impact - The timely introduction of the vaccine during the flu season will provide Macau residents with a reliable immunization option, contributing to the strengthening of public health defenses in the region [1] - The first vaccination ceremony held at the Macau Silver Quay Hospital emphasized the company's vision of making global innovative vaccines available in China and providing high-quality Chinese vaccines to the world [2] Group 3: Future Strategy - The successful delivery and implementation of the vaccine in Macau exemplify the solid advancement of the company's internationalization strategy, with established partnerships in multiple countries and regions [3] - The collaboration enhances the company's market presence in the Guangdong-Hong Kong-Macao Greater Bay Area and accumulates valuable experience for expanding international channels, contributing to global influenza prevention efforts [3]
突破！慧尔康欣首次出口澳门——四价流感病毒亚单位疫苗助力澳门地区健康防护